Navigation Links
Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
Date:12/13/2011

eral cases of QTc prolongation were reported early in the study, but most resolved following a dose adjustment, and no Grade 4 cases have been reported in the subset of 62 patients.  One case of Grade 4 QTc prolongation has been observed in the entire study of 333 patients.  Management of other adverse events is also being explored with dose modifications in the ongoing study.

Detection of Phosphorylated and Total FLT3 and STAT5 in Whole Blood;

Modulation by Quizartinib (AC220) from Phase I and II Trials in AML

The pharmacodynamic effects of quizartinib treatment in AML patients was assessed using whole blood samples from patients enrolled in a previously performed Phase 1 study, and from the 62 patient subset in the Phase 2 study described above.  Proprietary and customized immunoassays were developed, optimized and validated at Ambit to detect both total (t) and phosphorylated (p) levels of FLT3, as well as the downstream signaling protein STAT5.  Blood samples were examined prior to treatment with quizartinib on Day 1 of treatment and again after either 8 or 15 days of treatment, depending upon study. 

Results from this assay demonstrated that following administration of quizartinib there was a profound, immediate and sustained pharmacodynamic effect in inhibiting both FLT3 and the subsequent downstream phosphorylation of the biologically important signaling protein, STAT5.  A mean pFLT3 inhibition of 80 percent was observed within 24-hours of the first dose, and there was a strong correlation with inhibiting phosphorylation of STAT5 (p < 0.007).  These findings support the linkage between FLT3 activation and downstream STAT5 activation, and demonstrate the ability of quizartinib to inhibit both of these important signaling molecules that are involved in the pathology of FLT3-ITD positive AML.  Results at later time points showed that approximately one half (47 per
'/>"/>

SOURCE Ambit Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. Ambit Biosciences Announces Transition in Company Leadership
3. Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
4. Astellas Pharma Inc. to Acquire OSI Pharmaceuticals, Inc.
5. Astellas Awards Educational Scholarships to Six Transplant Recipients Who Embody the Spirit of Giving Back
6. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
7. CV Therapeutics Board of Directors Rejects Astellas Tender Offer
8. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
9. CV Therapeutics Board of Directors Rejects Astellas Unsolicited Proposal
10. CV Therapeutics Statement on Unsolicited Proposal From Astellas
11. FDA Approves Astellas Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed in 5% Dextrose for the Treatment of Hyponatremia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), ... proprietary technologies are used to discover, develop, manufacture ... bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, ... as Vice President and Chief Financial Officer. Tom ... information technology operations for Dyadic and will succeed ...
(Date:7/30/2014)... , July 30, 2014  AtheroNova Inc. (OTCBB: ... and development of compounds to safely regress atherosclerotic ... announces that its partner, CardioNova, has accomplished first ... trial with AtheroNova,s lead compound, AHRO-001.  This Phase ... AHRO-001 Phase 1 safety trial completed in February ...
(Date:7/30/2014)... July 30, 2014 Connecticut Center for ... based in East Hartford, Conn., was awarded a Rural ... of a project that will determine the feasibility of ... north-central Connecticut. USDA Rural Development provided $53,000 for CCAT ... the second phase of the feasibility study in fiscal ...
(Date:7/30/2014)... Immunology Summit-2014 will be ... scientists in the field, which includes prominent personalities ... Western Reserve University School of Medicine, USA, who ... “The effects of recombinant human IL-6 and recombinant ... Biragyn, a Senior investigator at National Institute on ...
Breaking Biology Technology:Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... GE Healthcare and Intermountain Health Care ... software program that would accelerate the adoption of electronic ... was announced at the annual Healthcare Information and Management ... companies hope to take the clinical knowledge that IHC ...
... next big thing is not enough. , ,Whether you're ... occupying several hard-won niches, or a high-energy start-up, protecting ... Miller, an intellectual property lawyer with Michael Best & ... eInnovate, a Milwaukee-based technology forum, Miller said some researchers ...
... Small Tree Communications , a niche hardware company that ... funding round from Chippewa Valley Angel Investors Network . ... our business faster by getting our products to market sooner," ... us to get office space and equipment, and to develop ...
Cached Biology Technology:GE and Intermountain want to streamline nationwide patient data 2Protect your intellectual property before it's too late 2Protect your intellectual property before it's too late 3Chippewa Valley angels invest in network hardware company 2Chippewa Valley angels invest in network hardware company 3
(Date:7/30/2014)... her eggs until they hatched 4.5 years later, according ... open-access journal PLOS ONE by Bruce Robison ... Octopuses typically have a single reproductive period during their ... their fertilized eggs until they hatch. Shallow-water octopuses typically ... but little is known about the brooding of deep-sea ...
(Date:7/30/2014)... two points is a straight line, and now Harvard ... familiar axiom to heart. , Though competition among ... each racing for the chance to fertilize the egg, ... groups that allow them to take a straighter path ... by Heidi Fisher, a post-doctoral student working in the ...
(Date:7/30/2014)... San Antonio Life Sciences Institute (SALSI), a joint venture ... and The University of Texas Health Science Center at ... Initiative Pilot Program. The winners, Emily Boice from UTSA ... receive $25,000 for their project titled, "Novel engineered ferritins ... environment." , Boice and Huang,s research is focused on ...
Breaking Biology News(10 mins):Deep-sea octopus has longest-known egg-brooding period 2When cooperation counts 2When cooperation counts 3
... A survey of bat activity in burned and unburned areas after ... evidence of detrimental effects on bats one year after the fire. ... some species may even benefit from the effects of fire on ... Frick of the University of California, Santa Cruz, will be published ...
... and Boston, MA. Wed. March 6, 2013 New ... and Women,s Hospital, Harvard University, MIT, and Yale University ... cell known as a T helper 17 or ... the development of immune responses. By figuring out how ...
... Scientists at the Salk Institute for Biological Studies have identified ... adapt to various environments, but could also benefit crop production ... in Nature , the findings show that in addition ... epigenomic makeup is as varied as the environments in which ...
Cached Biology News:Bats not bothered by forest fires, study finds 2Circuitry of cells involved in immunity, autoimmune diseases exposed 2Circuitry of cells involved in immunity, autoimmune diseases exposed 3Circuitry of cells involved in immunity, autoimmune diseases exposed 4Circuitry of cells involved in immunity, autoimmune diseases exposed 5Hidden layer of genome unveils how plants may adapt to environments throughout the world 2Hidden layer of genome unveils how plants may adapt to environments throughout the world 3
... to slightly cloudy liquid. Yellow, oily, ... set, each containing 10 ml of ... following proportions by weight: 85% Drakeol ... emulsifier), and 0.1% Mycobacterium butyricum ...
... Easy and Cost effective - Utilizes hands-off ... , No grinding - Extract DNA ... grinding tools between samples , Robust ... beat and homogenize without tube breakage , ...
... secretion of cytoplasmic granules, is a ... of leukocytes (e.g. basophils, neutrophils, eosinophils, ... histamine, these secretory granules contain many ... and many proteases (Hallgren, 2001). Tryptase, ...
... the things youll be telling others after you ... Erica Golemis, One look at the table of ... in protein interaction will tell you immediately that ... part of your personal protein chemistry library. You ...
Biology Products: